

Indivior's new schizophrenia drug may improve patient compliance

Écrit par GlobalData

Mercredi, 22 Mars 2017 21:29 -

GlobalData»

RBP-7000, a new pipeline drug developed by Indivior for the treatment of schizophrenia, has the poten

As explored in the company's [recent schizophrenia report](#), antipsychotic products currently on the mark

On 13th March 2017, Indivior announced that RBP-7000 had po

Rahael Maladwala, Associate Healthcare Analyst for GlobalData, explains: "On the back of these resul

Risperidone was originally marketed as Risperdal by Janssen Pharmaceuticals and is currently availab

Maladwala continues: "RBP-7000 looks to improve the compliance rate in schizophrenia sufferers by re

"While risperidone is a well-established drug for the treatment of schizophrenia, Indivior may face diffic